📊 Note: Daily ratings and analytics are updated after market close and will be available by 7:00 PM IST.

Details

NameSymbolSector
MEDICAMEN BIOTECH LTD.MEDICAMEQPharmaceuticals
Open
368
High
368.15
Low
347
Close
350.85
Volume
15443
Exchange
nse
Time
23-Jan-2026

Outlook

Score:

1

Rating:

RISKY

Candlestick Pattern

CandlepatternofMedicamenBiotechis
Opening Marubozu
EstimatedStoplossofMedicamenBiotechis
368.15
MedicamenBiotechhasa
Bearishℹ
pattern.
Formationof
Opening Marubozu
candlepatternindicatesMedicamenBiotechhaschancesof
Continuationℹ
ofthecurrenttrend.

Trend

MedicamenBiotechisin
Sideways trendℹ
.
PriceofMedicamenBiotechis
Downℹ
by

8.38

%.
Target
Buy@

352.75

Sell@

422.01

Current@

350.85

Volume

ThetradevolumesofMedicamenBiotechhavebecome
Deficientℹ
ThevolumetrendforMedicamenBiotechis
Bearishℹ
,buttheparticipantsare
Weak Sellersℹ
ThetradevolumeofMedicamenBiotechis

Down

by

64.86

%

Valuation

ThecurrentmarketpriceofMedicamenBiotechis
Overvaluedℹ

Financials

Balance
Withtotalliablitiesandshareholderequityworth297crandtotalassetsworth297cr,thebalancesheetofMedicamenBiotechis:
Balancedℹ
.
Cashflow
MedicamenBiotechhas
Badℹ
cashflowbecausethereis

Shortage

of

₹ 11cr

.Itis
Downℹ
by

120

%.
80% i.e. ₹ 8cr spent in operatingℹ
10% i.e. ₹ 1cr spent in investingℹ
10% i.e. ₹ 1cr spent in financingℹ
0% in otherℹ
MedicamenBiotechhas
Poorℹ
cashflowbecausethereis

Shortage

of

₹ 5cr

.Itis
Downℹ
by

131.25

%.
35.29% i.e. ₹ 6cr spent in operatingℹ
29.41% i.e. ₹ 5cr spent in investingℹ
35.29% i.e. ₹ 6cr earned in financingℹ
0% in otherℹ
Income
TheincomeofMedicamenBiotechis

₹ 47cr

and

Profit

is:

₹ 2cr

MedicamenBiotechProfitisupby:

100

%andIncomeisUpby:

9.3

%
TheincomeofMedicamenBiotechis

₹ 43cr

and

Profit

is:

₹ 1cr

MedicamenBiotechProfitisupby:

0

%andIncomeisUpby:

26.47

%
TheincomeofMedicamenBiotechis

₹ 34cr

and

Profit

is:

₹ 1cr

MedicamenBiotechProfitisdownby:

50

%andIncomeisDownby:

24.44

%
By using this site you agree to the use of cookies to deliver a better site experience.